Micafungin

Generic Name
Micafungin
Brand Names
Mycamine
Drug Type
Small Molecule
Chemical Formula
C56H71N9O23S
CAS Number
235114-32-6
Unique Ingredient Identifier
R10H71BSWG
Background

Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.

Indication

Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been...

Associated Conditions
Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis
Associated Therapies
-
Clinical Trials
Related News

Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients

Phase 4
Withdrawn
Conditions
Sepsis
Candidiasis
Interventions
Drug: Fluconazole
Drug: Micafungin
First Posted Date
2006-03-20
Last Posted Date
2024-06-14
Lead Sponsor
Kyoto University
Registration Number
NCT00304772
Locations
🇯🇵

Department of Clinical Laboratory Medicine, Kyoto University Hospital, Kyoto, Japan

Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia

First Posted Date
2005-09-19
Last Posted Date
2008-01-02
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
24
Registration Number
NCT00189709

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

Phase 3
Completed
Conditions
Candidiasis
Interventions
Drug: Micafungin
Drug: Liposomal Amphotericin B
First Posted Date
2005-03-23
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
637
Registration Number
NCT00106288

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Phase 3
Completed
Conditions
Candidiasis
Candidemia
Interventions
Drug: Micafungin
Drug: Caspofungin
First Posted Date
2005-03-08
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
611
Registration Number
NCT00105144

Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU

Phase 3
Terminated
Conditions
Invasive Fungal Infections
Interventions
Drug: Placebo
Drug: Micafungin
First Posted Date
2002-11-08
Last Posted Date
2012-03-27
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
104
Registration Number
NCT00048750

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Phase 2
Terminated
Conditions
Aspergillosis
Interventions
Drug: Micafungin
Drug: Liposomal Amphotericin B
First Posted Date
2002-10-24
Last Posted Date
2014-08-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
2
Registration Number
NCT00047827
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy